stockrow
Saturday 7 November 2026
Export KAPA’s income statement to Excel — free account
Kairos Pharma, Ltd.
KAPA Healthcare Biotechnology
- EPS
- +25.0%
- Free cash flow
- −25.7%
Quarter to June 2026, against a year earlier
0.49
0.04
+8.89%
Follow KAPA
Alert me
Kairos Pharma, Ltd. (KAPA) P/E ratio
Kairos Pharma, Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CARM Carisma Therapeutics Inc. compare | n/m |
| PPCB Propanc Biopharma Inc compare | n/m |
| XRTX XORTX Therapeutics Inc. compare | n/m |
| GOVX GeoVax Labs Inc. compare | n/m |
| KAPA Kairos Pharma, Ltd. | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| ITRMF Iterum Therapeutics PLC compare | n/m |
| OGEN Oragenics, Inc. compare | n/m |
| ABPO Abpro Holdings Inc. compare | 0.5× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)